Sterling Pharma Solutions Acquires ADC Biotechnology
April 7, 2021
Sterling Pharma Solutions, a GHO Capital portfolio CDMO, has acquired ADC Biotechnology (ADC Bio), a Deeside-based bioconjugation and ADC development services business. The deal adds ADC capabilities and a Deeside facility to Sterling’s international network and includes multi-million pound investment to grow bioconjugation, analytical and cGMP ADC manufacturing capabilities.
- Targets
- ADC Biotechnology
- Platforms
- Sterling Pharma Solutions
- Industry
- Biotechnology
- Location
- Wales, United Kingdom
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.